sch 16134 has been researched along with zopiclone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Morel, E; Perrault, G; Sanger, DJ; Zivkovic, B | 1 |
2 other study(ies) available for sch 16134 and zopiclone
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Azabicyclo Compounds; Azepines; Benzodiazepines; Central Nervous System Depressants; Dose-Response Relationship, Drug; Eating; Hypnotics and Sedatives; Male; Mice; Mice, Inbred Strains; Piperazines; Pyridines; Receptors, GABA-A; Zolpidem | 1990 |